JERUSALEM, Dec. 5 (Xinhua) -- Jerusalem-based Teva Pharmaceuticals and U.S.-based Galena Biopharma are set to begin major clinical trials of a breast cancer treatment that holds promise of vaccination against several varieties of the disease, local media reported on Wednesday.
The study of the NeuVax Phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to- Intermediate HER2 Expression with NeuVax Treatment) formula are expected to be held at four locations in Israel, according to a statement released by the two firms.
"We are embarking on a very exciting and innovative venue for the adjuvant treatment of early breast cancer," said Noa Efrat Ben- Baruch, head of the Department of Oncology at Kaplan Medical Center, near Tel Aviv.
"In this study we are boosting the body's natural immune system to deal with possible residual cancer cells still present. The biological reasoning behind this treatment is sound," she said. " We hope that the results of this large randomized study will confirm the encouraging results seen in earlier studies using this agent."